| Member | Role | Affiliation | Country | Profile |
|---|---|---|---|---|
Dr. Ram Krishna Sai
|
Editorial Board Member | Medical Oncology, Mahatma Gandhi University | India | |
Prof. Dr. Karthik S. Udupa
|
Editorial Board Member | Department of Medical Oncology, Kasturba Medical College | India | |
Prof. Malathy Puthan Shekhar
|
Editorial Board Member | School of Medicine-Oncology, Wayne State University | USA | |
Prof. Nathaniel Bouganim
|
Editorial Board Member | Dept of Oncology, McGill University | Canada | |
Prof. Priya Ramanathan
|
Editorial Board Member | Dept of Molecular Oncology, The Adyar Cancer Institute | India |
Dr. Ram Krishna Sai
I had experience in treating Cancer patients with Chemotherapy, Immunotherapy, Targeted agents, and Hormonal therapy. I had previous experience of treating cancer patients at institutions like SMS HOSPITAL, State cancer institute, JNU Hospital, NIMS Hospital and other corporate Hospitals.
Prof. Dr. Karthik S. Udupa
Area of Interest
Childhood Cancer, Ovarian and Breast Cancer, Bone Marrow Transplantation
Area of Expertise
Leukemias and Lymphomas
Area of Research
Neoadjuvant chemotherapy in Breast Cancer
Childhood Cancer, Ovarian and Breast Cancer, Bone Marrow Transplantation
Area of Expertise
Leukemias and Lymphomas
Area of Research
Neoadjuvant chemotherapy in Breast Cancer
Prof. Malathy Puthan Shekhar
Research interests
The long term goal of our research is to understand the molecular and cellular basis of breast cancer development and therapy response/resistance mechanisms. Our laboratory uses in vivo and in vitro three-dimensional breast cancer culture systems to investigate host stromal interactions and their role in breast cancer development, progression and hormonal response. We identified Rad6B, an ubiquitin conjugating enzyme, and a fundamental component of postreplication DNA repair pathway, to play a critical role in breast cancer development, progression and chemosensitivity. Studies from our laboratory also uncovered a novel function for Rad6B in beta-catenin stabilization and transcriptional activation. Interestingly, Rad6B is a transcriptional target of beta-catenin, thus revealing a positive feedback loop between Rad6B gene expression and beta-catenin stabilization. We have recently identified a small molecule inhibitor of Rad6, and our current studies are focused on unraveling crosstalk between BRCA/Fanconi anemia and Rad6 DNA repair pathways in triple negative breast cancer.
The long term goal of our research is to understand the molecular and cellular basis of breast cancer development and therapy response/resistance mechanisms. Our laboratory uses in vivo and in vitro three-dimensional breast cancer culture systems to investigate host stromal interactions and their role in breast cancer development, progression and hormonal response. We identified Rad6B, an ubiquitin conjugating enzyme, and a fundamental component of postreplication DNA repair pathway, to play a critical role in breast cancer development, progression and chemosensitivity. Studies from our laboratory also uncovered a novel function for Rad6B in beta-catenin stabilization and transcriptional activation. Interestingly, Rad6B is a transcriptional target of beta-catenin, thus revealing a positive feedback loop between Rad6B gene expression and beta-catenin stabilization. We have recently identified a small molecule inhibitor of Rad6, and our current studies are focused on unraveling crosstalk between BRCA/Fanconi anemia and Rad6 DNA repair pathways in triple negative breast cancer.
Prof. Nathaniel Bouganim
Clinical Interests:
Medical Oncology; Breast Cancer; Head and Neck Cancer; Hepatobilliary Cancer
Current research:
Breast Cancer; Head and Neck Cancer; Hepatobilliary Cancer
Medical Oncology; Breast Cancer; Head and Neck Cancer; Hepatobilliary Cancer
Current research:
Breast Cancer; Head and Neck Cancer; Hepatobilliary Cancer
Prof. Priya Ramanathan
Research Interest
> Dendritic cell-based immunotherapy
> Tumor infiltrating cell-based immunotherapy
> CAR-T cell therapy
> Tumor microenvironment
> Dendritic cell-based immunotherapy
> Tumor infiltrating cell-based immunotherapy
> CAR-T cell therapy
> Tumor microenvironment